Related Experiment Video
Updated: May 8, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Interactions between Aβ and mutated Tau lead to polymorphism and induce aggregation of Aβ-mutated tau oligomeric
1Department of Chemistry, Ben‑Gurion University of the Negev, Beer-Sheva, Israel.
Abstract:
One of the main hallmarks of the fronto-temporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) is the accumulation of neurofibrillary tangles in the brain as an outcome of the aggregation of mutated tau protein. This process occurs due to a number of genetic mutations in the MAPT gene. One of these mutations is the ∆K280 mutation in the tau R2 repeat domain, which promotes the aggregation vis-à-vis that for the wild-type tau. Experimental studies have shown that in Alzheimer's disease Aβ peptide forms aggregates both with itself and with wild-type tau. By analogy, in FTDP-17, it is likely that there are interactions between Aβ and mutated tau, but the molecular mechanisms underlying such interactions remain to be elucidated. Thus, to investigate the interactions between Aβ and mutated tau, we constructed fourteen ∆K280 mutated tau-Aβ17-42 oligomeric complexes. In seven of the mutated tau-Aβ17-42 oligoemric complexes the mutated tau oligomers exhibited hydrophobic interactions in their core domain, and in the other seven mutated tau-Aβ17-42 oligoemric complexes the mutated tau oligomers exhibited salt-bridge interactions in their core domain. We considered two types of interactions between mutated tau oligomers and Aβ oligomers: interactions of one monomer of the Aβ oligomer with one monomer of the mutated tau oligomer to form a single-layer conformation, and interactions of the entire Aβ oligomer with the entire mutated tau oligomer to form a double-layer conformation. We also considered parallel arrangements of Aβ trimers alternating with mutated tau trimers in a single-layer conformation. Our results demonstrate that in the interactions of Aβ and mutated tau oligomers, polymorphic mutated tau-Aβ17-42 oligomeric complexes were observed, with a slight preference for the double-layer conformation. Aβ trimers alternating with mutated tau trimers constituted a structurally stable confined β-structure, albeit one that was energetically less stable than all the other constructed models.
Insights
This study investigates interactions between amyloid-beta (Aβ) and mutated tau protein in fronto-temporal dementia. Researchers modeled tau-Aβ complexes, revealing polymorphic structures with a preference for double-layer conformations.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Fronto-temporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) is characterized by neurofibrillary tangles from mutated tau protein aggregation.
- Genetic mutations in the MAPT gene, such as ∆K280 in the tau R2 repeat, enhance tau aggregation.
- Alzheimer's disease involves amyloid-beta (Aβ) aggregation with wild-type tau, suggesting potential interactions with mutated tau in FTDP-17.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying interactions between Aβ and mutated tau.
- To investigate the structural characteristics of tau-Aβ oligomeric complexes.
Main Methods:
- Construction of fourteen ∆K280 mutated tau-Aβ17-42 oligomeric complexes.
- Modeling of complexes with hydrophobic or salt-bridge interactions in the mutated tau core.
- Consideration of single-layer (monomer-monomer) and double-layer (oligomer-oligomer) conformations, as well as alternating trimer arrangements.
Main Results:
- Observed polymorphic mutated tau-Aβ17-42 oligomeric complexes.
- A slight preference for the double-layer conformation was noted.
- Alternating arrangements of Aβ and mutated tau trimers formed stable β-structures, though energetically less favorable than other models.
Conclusions:
- Interactions between Aβ and mutated tau can lead to diverse oligomeric complex structures.
- The double-layer conformation appears to be a preferred structural arrangement.
- Understanding these interactions is crucial for elucidating FTDP-17 pathogenesis.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Parkinson Disease ll: Pathophysiology

